| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/28/2004 | EP1411952A1 Use of at least one glycoinhibitor substance |
| 04/28/2004 | EP1411945A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1411943A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 04/28/2004 | EP1411941A2 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1411938A1 Use of cyclopamine in the treatment of psoriasis |
| 04/28/2004 | EP1411929A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 04/28/2004 | EP1411927A1 Method for the preparation of selectively-substituted corroles and new substituted corroles |
| 04/28/2004 | EP1411919A1 (-)-olivil as antioxidant |
| 04/28/2004 | EP1411918A2 Methods to mobilize progenitor/stem cells |
| 04/28/2004 | EP1411910A1 (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 04/28/2004 | EP1411909A1 Pharmaceutical composition comprising (-)-secoisolariciresinol |
| 04/28/2004 | EP1411907A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 04/28/2004 | EP1411905A1 Sustained release delivery system |
| 04/28/2004 | EP1411904A1 Sustained release pharmaceutical composition |
| 04/28/2004 | EP1411898A1 Pharmaceutical composition comprising lipids with a polar and a nonpolar moiety |
| 04/28/2004 | EP1411897A2 Compositions and methods for intracellular delivery |
| 04/28/2004 | EP1411880A2 Recombinant vsv for the treatment of tumor cells |
| 04/28/2004 | EP1411817A2 Method and apparatus for the photomodulation of living cells |
| 04/28/2004 | EP1286684B1 use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| 04/28/2004 | EP1263718B1 Novel use of phenylheteroalkylamine derivatives |
| 04/28/2004 | EP1263715B1 Novel phenylheteroalkylamine derivatives |
| 04/28/2004 | EP1250147B1 Interferon-alpha use in the treatment of ewing's sarcoma |
| 04/28/2004 | EP1227098B1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 04/28/2004 | EP1208096B1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 04/28/2004 | EP1206448B1 Novel vitamin d analogues |
| 04/28/2004 | EP1162981B1 Dexrazoxane for the treatment of accidental extravasation of anthracyclines |
| 04/28/2004 | EP1153024B1 2-amino-6-anilino-purines and their use as medicaments |
| 04/28/2004 | EP1140197B1 Soluble compositions of toremifene |
| 04/28/2004 | EP1087970B1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 04/28/2004 | EP0937045B1 N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity |
| 04/28/2004 | EP0910645B1 A KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF I-kappa-B-alpha |
| 04/28/2004 | EP0777498B1 Conjugates made of metal complexes and oligonucleotides |
| 04/28/2004 | EP0655925B1 Anti-cancer therapeutic compositions containing whey protein concentrate |
| 04/28/2004 | EP0558648B1 Improved matrix metalloprotease inhibitors |
| 04/28/2004 | CN1492926A Preferred segments of neural thread protein and methods of using the same |
| 04/28/2004 | CN1492875A TTK in diagnosis and as a therapeutic target in cancer |
| 04/28/2004 | CN1492872A Tricycle quinolinone and tricycle quinoline as androgen receptor modulator compounds |
| 04/28/2004 | CN1492869A Tricyclic androgen receptor modulator compounds and method |
| 04/28/2004 | CN1492860A 喹唑啉衍生物 Quinazoline derivatives |
| 04/28/2004 | CN1492767A Modified anti-EGFR antibody with reduced immunogenicity |
| 04/28/2004 | CN1492762A Azoles as malonyl-COA decarboxylase inhibitors useful as metabolic modulators |
| 04/28/2004 | CN1492758A Method and formula for anti-tumor and anti-matastatic effect |
| 04/28/2004 | CN1492756A Amphoteric liposomes and the use thereof |
| 04/28/2004 | CN1492737A Functional agent for decomposing nicotine and method of preparing the same |
| 04/28/2004 | CN1492735A Non invasive measurements of chemical substances |
| 04/28/2004 | CN1491961A Amaranth seed ribosome inactivating protein |
| 04/28/2004 | CN1491947A C10 ester carbonate substituted taxadane |
| 04/28/2004 | CN1491941A Heterobicyclic sulfonamide derivative and sulfonic ester derivative |
| 04/28/2004 | CN1491722A Compound alliin powder injection |
| 04/28/2004 | CN1491694A Anti-cancer medicine and its producing method |
| 04/28/2004 | CN1491671A Medicinal composition for treating liver cancer and pancreatic cancer and its preparing method |
| 04/28/2004 | CN1491651A Use of 23-hydroxy betutic acid in preparing medicine for treating and preventing tumour and AIDS |
| 04/28/2004 | CN1491643A Medicine for treating and preventing tumour metastasis and using method |
| 04/28/2004 | CN1147493C Oxazolo, thiazole and selenazolo [4,5-C]-quinolin-4-amines and analoges thereof and pharmaceutical composition containing them |
| 04/28/2004 | CN1147492C New metal protease inhibitors its preparing method and their medicinal composition containing them |
| 04/28/2004 | CN1147491C Acridine carboxylic ester compound, preparation and medicinal composition thereof |
| 04/28/2004 | CN1147481C Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases |
| 04/28/2004 | CN1147472C Benzamide formulation with histone deacetylase inhibitor activity |
| 04/28/2004 | CN1147317C Combination of tyrosine kinase inhibitor and chemical castration and its use in pharmaceutical production |
| 04/28/2004 | CN1147305C Extracts of shark cartilage having anti-angiogenic activity and effect on tumor regression, process of making thereof |
| 04/28/2004 | CN1147300C Vitronectin receptor antagonist |
| 04/28/2004 | CN1147299C Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 04/28/2004 | CN1147294C Pentafluorobenzenesulfonamides and analogs |
| 04/27/2004 | US6727352 Methods of making macrolides |
| 04/27/2004 | US6727350 Toso |
| 04/27/2004 | US6727347 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body |
| 04/27/2004 | US6727287 Comprising less than 10% by weight of a toluene sulfonamide and a pharmaceutically acceptable carrier |
| 04/27/2004 | US6727276 Epothilone derivatives for the treatment of refractory tumors |
| 04/27/2004 | US6727275 Pyrrolidinone derivatives |
| 04/27/2004 | US6727273 Therapy for osteoporosis, anticancer agents |
| 04/27/2004 | US6727269 Acromegaly, pituitary adenoma or endocrine gastroenteropanceatic tumors including the carcinoid syndrome, and gastrointestinal bleeding |
| 04/27/2004 | US6727268 Cyclooxygenase inhibitors; antipyretic, analgesic, antiinflammatory, and anticarcinogenic agents |
| 04/27/2004 | US6727256 4-aminoquinazoline derivatives as anticarcinogenic agents |
| 04/27/2004 | US6727253 Use of a topo ii catalytic nhibitor such as the bisdioxopiperazine icrf-187, a quinoline, aclarubicin, and an acridine. |
| 04/27/2004 | US6727252 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
| 04/27/2004 | US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 04/27/2004 | US6727250 Administering compounds such as trans-3-(naphth-2-yl)-but-2-enoic acid-n-(2-carboxy-phenyl)-amide or like for therapy of conditions associated with increased telomerase activity, e.g. tumour diseases |
| 04/27/2004 | US6727245 Heterobicyclic derivatives |
| 04/27/2004 | US6727239 Inhibitory activity on no- synthase enzymes producing nitrogen monoxide no and/or an activity which traps the reactive oxygen species (ros) |
| 04/27/2004 | US6727233 Administering 1-hydroxy-2-(imidazo(1,2-a)pyridin-3-yl)ethane-1,1-bisphosphonic acid |
| 04/27/2004 | US6727226 Conotoxin peptide extracted from the venom of a marine snail, conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics |
| 04/27/2004 | US6727225 TWEAK receptor |
| 04/27/2004 | US6727064 Antiinflammatory agents; anticarcinogenic agents |
| 04/27/2004 | US6727059 Method for controlling the fidelity and processivity of reverse transcriptase by incorporation and polymerization of nucleotide analogs accepted as substrates for the reverse transcription reaction without blocking its elongation |
| 04/27/2004 | US6726938 Fagopyrum cymosum (Trev.) Meisn composition, method to prepare and analyze the same and uses thereof |
| 04/27/2004 | US6726925 Bi-layer membrane comprising phospholipid and lysolipid; drug delivery, medical diagnosis |
| 04/27/2004 | US6726895 Tumor radiotherapy |
| 04/27/2004 | CA2317530C Dysuria remedies |
| 04/27/2004 | CA2177732C Antisense oligonucleotides having tumorigenicity-inhibiting activity |
| 04/27/2004 | CA2109796C Modulation of cellular response to external stimuli |
| 04/27/2004 | CA2103708C Treatment of ovarian cancer |
| 04/24/2004 | CA2446094A1 Pharmaceutical dosage form and method of making |
| 04/22/2004 | WO2004034023A2 Methods of synthesizing 3-amino-1,2,4-benzotriazines |
| 04/22/2004 | WO2004033696A2 Recombinant adenoviral vectors and applications thereof |
| 04/22/2004 | WO2004033686A1 Novel protein and dna thereof |
| 04/22/2004 | WO2004033681A1 Substance having activity of promoting platelet aggregation |
| 04/22/2004 | WO2004033674A1 Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances |
| 04/22/2004 | WO2004033620A2 Methods and compositions for therapeutic use of rna interference |
| 04/22/2004 | WO2004033499A1 Cell death-inducing agent |
| 04/22/2004 | WO2004033465A1 2' oxo-voruscharin and derivatives thereof |